Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Recruiting

Phase 2

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Sponsor:

University of Kansas Medical Center

Code:

NCT06364176

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Losartan

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information